Possible Ameliorative Effect of Antioxidant (Taurine) in Pregnant Toxemic Female Rats

Ibrahim M.A. El-Agousa1, Dalia E. El-Nashar*,2, Saad, S. Eissa3 and Mona N. Sharoud4

1Faculty of Science, Zoology Department, Cairo University, Egypt
2Health Radiation Research, National Center for Radiation Research and Technology (NCRRT). Atomic Energy Authority, Cairo, Egypt
3National Cancer Institute, Cairo University, Egypt
4Biological Application Department, Atomic Energy Authority, Cairo, Egypt

Abstract: The present study was designed to investigate the possible effects of the antioxidant taurine on pregnant adriamycin (ADR) induced toxemic female rats. ADR was injected intraperitoneally to 50 pregnant female rats (5 groups) to induce toxemia. the first is Frank control group injected only with saline; the second group is the Taurine group that determined the effect of taurine alone; the third group is the Toxemic group that showed the toxicity of Adriamycin; the fourth group is the Therapeutic group (Adriamycin followed by Taurine) and the fifth group is the Protective group (Taurine followed by Adriamycin) that showed the amelurative effect of taurine in these groups.

Blood pressure, liver and kidney function, lipid profile, taurine concentration in plasma, serum cortisone, T3 &T4 were measured for all animals. Furthermore, histopathological examination and morphometric study for liver, kidney and cardiac muscle were done for all groups.

The results showed that, the Protective group has marked improvement in most biochemical parameters than the Therapeutic group compared to Toxemic group.

Morphometric study revealed a significant decrease in the nuclear area in the tissues of toxemic rats. Also, marked disturbances were observed in the histopathological architecture of the kidney, liver and heart in all toxemic rats. However, a marked improvement in morphometrical parameters and histopathological architecture was observed in protective group. The results support the ameliorative effect of taurine in the protection against toxemia during pregnancy in experimental animals.

Keywords: Hypertension, pregnant toxemia, antioxidant taurine.

INTRODUCTION

Hypertension is a common problem facing pregnant females today. Because high blood pressure is a major risk for heart attack since it causes damage to the blood vessels, heart, kidney, eyes and other organs [1]. So, hypertension (high blood pressure), is a condition commonly associated with narrowing of the arteries. This causes blood to be pumped with excessive force against the artery walls. It is called "Silent killer" because most people have no reason to think they might be hyper tensive [2].

Toxemia during pregnancy, or the so-called pregnancy induced hypertension (PIH), is a challenging clinical state, which complicates approximately 10% of all pregnancies. PIH remains a major cause of morbidity and mortality for both mother and fetus [3].

Recently, the multisystem nature of this unique gestational disorder has been emphasized. But widespread vascular endothelial dysfunction and vasospasm, considered as one of the basics pathophysiology of this syndrome [4, 5]. Adriamycin is one of the chemotherapeutic drugs that are given as treatment for many forms of cancers, but unfortunately it has many side effects [6]. Special attention must be given to the nephrotoxicity persuaded by adriamycin that results in hypertension.

Taurine is a major free intracellular amino acid present in many tissues, and now it has been shown to be involved in many important physiological functions in the development of the CNS [7]; maintaining the structural integrity of the cell membrane [8]; regulating Ca++ binding and transport [9, 10] specially in cardiac muscle [11]; as an osmolyte [12, 13] and neurotransmitter [14, 15]. In the last decade it has been proved that taurine plays an important role in protecting liver [16-19] kidney tissues [20-23] and cardiac muscle [11]; from different hepatotoxic, nephrotoxic and cardiotoxic substances in addition to well established hypolipidemic [24-26] and hypoglycemic effects [27-30].

The target of the present investigation was to visualize the possible effects of antioxidant (taurine) in pregnant adriamycin (ADR) induced toxemia in female rats. The
results of which could direct the attention to the management of toxemia during pregnancy, which remains a major challenge of gynecologists.

**MATERIAL AND METHODS**

One hundred virgin female albino rats (Rattus rattus), 10-12 weeks old body weight between 140-160 gm were randomly selected from a large population of animals. The animals were fed on a standard laboratory rodent diet (NRC) and fresh tap water.

The estrus phase was tested by vaginal smear from virgin females. Mating was allowed at a ratio of one male to three female rats in every cage during the estrus phase. The detection of pregnancy was carried out by the two following methods, and animals were considered pregnant when both methods confirmed positive results.

i. The vaginal smear method: A vaginal smear was spread on a glass slide with a drop of distilled water, and then dried in air. The dried smear was stained by hematoxylin 0.2% (0.2gm hematoxylin dissolved in 100ml distilled water), dried in air and examined microscopically for sperm detection.

ii. The vaginal plug method: The presence of a plug in the vagina confirmed the occurrence of mating and was recorded as the first day of gestation.

The pregnant rats were classified into five groups (ten animals each):

- **Group I (control group):** pregnant rats were given only saline all through the gestation period.
- **Group II (Taurine group):** pregnant rats were daily injected intraperitoneally (i.p) with 500mg/Kg B.wt. taurine, all through the gestation period (about 23±2 days).
- **Group III (Toxemic pregnant group):** pregnant rats were daily injected (i.p) with cumulative dose of adriamycin (10mg/Kg B.wt.), which divided into 6 equal injections over a period of two weeks according to the method of Podjarny [31].
- **Group IV (Therapeutic group):** pregnant rats were injected with Adriamycin and after two days taurine was administered.
- **Group V (Protective group):** pregnant rats were injected with ADR, but 2 days previously had been treated with taurine in the doses as in taurine group.

During the experimental period the tail systolic blood pressure was determined by tail-cuff plethysmograph in unanesthetized rats model LE5001-pressure meter, Letica, SA, Spain.

Blood samples were drawn, after overnight fasting (using a special micropipettes introduced through the inner contuse of rats orbit into the cavernous sinus and the head of the rat was tilted down) in clean, and sterile serum tubes. Blood samples were centrifuged for 10 minutes, at 3000 r.p.m. within an hour of the blood collection and the sera were obtained. Each serum was divided into small fractions, which were kept in deep freezer under -20°C for analysis of the following different parameters, lipid profile, and taurine concentration in serum were determined, while liver function parameters have been done before freezing for all animals.

**RIA for T3&T4 & Cortisone Hormones**

T3, T4 & cortisone levels were determined by using the commercial radio immuno assay Kit (RIA) [32].

**Histopathological Studies**

After scarification and dissection, kidney, liver, and heart were removed immediately and fixed in 10% normal saline and neutral buffered formalin for 7 days, then the tissues were washed and dehydrated in ascending grades of ethyl alcohol cleared in benzene and impregnated in paraffin for 1.5 hour in the oven at 55°C. Serial section, 5µm were cut and stained with Hematoxylin & Eosin (H&E) as described by [33].

**Pathology Score**

According to pathology of [34] the histopathological changes in the tissues of kidney, liver and heart were grouped in three classes: minimal, moderate and severe changes.

Score I refers to minimal changes, score II to moderate changes, while score III to severe changes.

Score I characterized by changes only in the intercellular space and blood vessels, but in score II the pathological changes affect the cell membrane up to vacuolization in cytoplasmic, while nuclear degenerative changes occur only in score III.

**Morphometric Study**

Thirty cases were subjected to morphometric study by CAS-200 image cytometry using the micrometer program plus software package (Version 1.0). This was carried out on the H&E stained tissue sections at an objective magnification of 40x for each case. At least one hundred nuclei were selected from the most typical histological fields. The nuclear areas were measured using the (point to point) and (point and click area) modes.

Mean nuclear area and SD for each case, and the variances of the measurements were calculated. The guidelines followed were that of [35,36].

**Statistical Analysis**

After confirmation of normal distribution for all variables, the significance of differences was evaluated by paired t-test or analysis of variance (ANOVA). Relationships between variables were analyzed by simple correlation analysis. Data are expressed as mean ±SD, and a value of P<0.05 was the criterion for statistical significance. All statistical analyses were performed using state view-j software on a computer.

**RESULTS**

The present investigation was carried out to examine the possible therapeutic and protective effects of taurine as an antioxidant, in ameliorating the common side effect of toxemia during pregnancy.

Blood pressure in Table 1 showed highly significant elevation in toxemic group as compared to control group,
while in therapeutic and protective groups the blood pressure were markedly decreased than that recorded in toxemic group.

Kidney functions in Table 2 showed highly significant elevation in blood urea and creatinine in all Adriamycin treated groups (Toxemic, Therapeutic and Protective groups) as compared to control group. However, both blood urea and creatinine showed marked enhancement in Protective group than in Therapeutic group as compared to that observed in Toxemic group.

Table 1. Therapeutic and Protective Effects of Taurine on Blood Pressure of Pregnancy Rats Injected with ADR

<table>
<thead>
<tr>
<th></th>
<th>Control (n=10)</th>
<th>T (n=10)</th>
<th>ADR (n=10)</th>
<th>ADR-T (n=10)</th>
<th>T-ADR (n=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood pressure</td>
<td>107.7±0.51</td>
<td>106±0.96</td>
<td>142.76±2.65</td>
<td>120±1.17</td>
<td>110.8±0.94</td>
</tr>
</tbody>
</table>

Possible Ameliorative Effect of Antioxidant (Taurine) The Open Hypertension Journal, 2009, Volume 2

The nephropathy scores of different adriamycin treated groups were shown in Table 3. In toxemic group, 10 rats showed lesions with score of III in 2 rats score II in 3 rats and score I in 5 rats. However, these nephritic lesions were alleviated in the groups where taurine either protectively or therapeutically was given in Table 3.

Plate I (Fig. 1), taurine (Fig. 2), and adriamycin (Fig. 3a, b) effects on liver tissue. Cellular and nuclear pleomorphism and apparent vacuolation in the cytoplasm of the hepatocytes were recorded in toxemic group. The hepatocytes in numerous hepatic lobules showed variation in nuclear size: some have small nuclei whereas in other the cells were large with longer nuclei. The blood vessels are congested with an increase in Kupffer cells. At the peripheral zones of the hepatic lobules, the hepatocytes were markedly vacuolated.

Table 2. Therapeutic and Protective Effects of Taurine in Pregnant Rats Kidney Injected with Adriamycin

<table>
<thead>
<tr>
<th></th>
<th>Urea (mg/dl)</th>
<th>Creatinine (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control Group</td>
<td>T Group</td>
</tr>
<tr>
<td></td>
<td>(n=10)</td>
<td>(n=10)</td>
</tr>
<tr>
<td>Urea (mg/dl)</td>
<td>21.10±4.18</td>
<td>23.70±3.62 a*</td>
</tr>
<tr>
<td>Creatinine (mg/dl)</td>
<td>0.54±0.16</td>
<td>0.16±0.16</td>
</tr>
</tbody>
</table>

Data are expressed as mean ±SD.

Table 3. Nephropathy Score in Different Adriamycin Treated Groups

<table>
<thead>
<tr>
<th>Groups</th>
<th>Score 0</th>
<th>Score 1</th>
<th>Score 2</th>
<th>Score 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toxemic Group (n=10)</td>
<td>0</td>
<td>5</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Therapeutic group (n=10)</td>
<td>0</td>
<td>5</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Protective group (n=10)</td>
<td>0</td>
<td>7</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

Plate II shows the normal (Fig. 1), taurine (Fig. 2), and adriamycin (Fig. 3a, b) effects on liver tissue. Cellular and nuclear pleomorphism and apparent vacuolation in the cytoplasm of the hepatocytes were recorded in toxemic group.
Plate (I). Histopathological changes in rat’s kidney tissue treated with Adriamycin and Taurine.

Fig. (1). Normal kidney showed a patent glomeruli and intact tubules (H & E, x 225).

Fig. (2). Kidney of rat after taurine administration showed normal appearance of glomeruli and tubules (H & E, x 225).

Fig. (3). Kidney of rat after ADR administration showed necrosis of the epithelial lining of the tubules and obliteration of the glomerular capillaries and adhesions of the glomerular epithelium with massive vacuolization in the cytoplasm (H & E, x 225).
Table 4. Therapeutic and Protective Effects of Taurine in Pregnant Rats Liver Injected with Adriamycin

<table>
<thead>
<tr>
<th></th>
<th>Control Group (n=10)</th>
<th>Taurine Group (n=10)</th>
<th>Toxemic Group (n=10)</th>
<th>Therapeutic Group (n=10)</th>
<th>Protective Group (n=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AST (u/l)</strong></td>
<td>127.95±15.47</td>
<td>112.50±10.61</td>
<td>201.60±19.05 a***</td>
<td>177.20±15.55 a*** b*** c***</td>
<td>163.30±18.03a*** b*** c***</td>
</tr>
<tr>
<td><strong>ALT (u/l)</strong></td>
<td>37.30±6.74</td>
<td>32.45±7.72</td>
<td>69.68±7.67 a***</td>
<td>60.05±7.19 a*** b*** c***</td>
<td>55.65±8.23a*** b*** c***</td>
</tr>
<tr>
<td><strong>ALP (u/l)</strong></td>
<td>27.90±4.68</td>
<td>27.65±4.18</td>
<td>70.25±5.99 a***</td>
<td>60.65±6.81 a*** b*** c***</td>
<td>52.05±4.59a*** b*** c***</td>
</tr>
<tr>
<td><strong>Bilirubin (mg/dl)</strong></td>
<td>0.67±0.14</td>
<td>0.66±0.10</td>
<td>1.06±0.18 a***</td>
<td>1.04±0.21 a*** b***</td>
<td>1.01±0.22a*** b***</td>
</tr>
</tbody>
</table>

Plate II. Histopathological changes in rat's liver tissue treated with Adriamycin and Taurine.

Fig. (1). Normal liver of the rat (control) showed the normal architecture of hepatocytes (H & E, x 225).

Fig. (2). Liver of rat after taurine administration showed normal architecture of hepatocytes (H & E, x 225).

Fig. (3a). Liver of rat after ADR administration showed the cytoplasmic vacuolization and fat degeneration of hepatocytes involving most of hepatic lobule and dilatation in the sinusoidal spaces with congested blood vessels (H & E, x 225).

Fig. (3b). Liver rat after ADR administration showed the extensive diffuse fat degeneration and hyperplasia in Kupffer cells (H & E, x 225).
Table 5. Hepatological Score in Different Adriamycin Treated Rats

<table>
<thead>
<tr>
<th>Groups</th>
<th>Score 0 Number of No Changes</th>
<th>Score I Number of Minimal Changes</th>
<th>Score II Number of Moderate Changes</th>
<th>Score III Number of Sever Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toxemic group (n=10)</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td>Therapeutic group (n=10)</td>
<td>0</td>
<td>1</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>Protective group (n=10)</td>
<td>0</td>
<td>2</td>
<td>5</td>
<td>3</td>
</tr>
</tbody>
</table>

Data are expressed as mean ±SD

<table>
<thead>
<tr>
<th>Groups</th>
<th>Control Group (n=10)</th>
<th>Taurine Group (n=10)</th>
<th>Toxemic Group (n=10)</th>
<th>Therapeutic Group (n=10)</th>
<th>Protective Group (n=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>T.Ch. (mg/dl)</td>
<td>55.25±4.28</td>
<td>42.25±7.33a***</td>
<td>98.95±10.98a***</td>
<td>90.65±6.23a***,b***</td>
<td>79.15±6.62a***,b***,c***,d***</td>
</tr>
<tr>
<td>TG. (mg/dl)</td>
<td>44.90±7.50</td>
<td>43.15±8.4</td>
<td>90.05±8.28a***</td>
<td>79.05±7.09a***,b***,c***</td>
<td>72.45±8.30a***,b***,c***,d***</td>
</tr>
<tr>
<td>HDL (mg/dl)</td>
<td>13.20±2.36</td>
<td>11.50±1.72</td>
<td>19.70±2.57a**</td>
<td>17.70±2.39a**,b**</td>
<td>18.00±2.7a**,b***,c***,d**</td>
</tr>
<tr>
<td>LDL (mg/dl)</td>
<td>32.95±4.52</td>
<td>21.33±3.31a***</td>
<td>63.69±6.72a***</td>
<td>56.96±5.94a***,b***</td>
<td>45.24±4.04a***,<strong>b</strong>*,c***,d***</td>
</tr>
<tr>
<td>VLDL (mg/dl)</td>
<td>6.63±1.40</td>
<td>6.05±1.23</td>
<td>12.53±1.69a***</td>
<td>11.37±1.68a**,b***</td>
<td>8.99±1.51a***,<strong>b</strong>*,c***,d**</td>
</tr>
</tbody>
</table>

Regarding to lipid parameters, in Table 6 showed marked elevation in all of them in toxemic group. These elevations were significantly decreased in rats therapeutically treated with taurine. Attractively, lipid parameter in protective group showed a difference markedly lower than that recorded in toxemic or therapeutic groups (Table 6).

The main cardiac pathological changes identified with ADR administration were myofibrillar loss and cytoplasmic vacuolization Plate III (Fig. 3a, b) examined by light microscope. However, Plate VI (Fig. 4a, b, c) showed moderate degrees of necrosis of the cardiac muscle of rat after adriamycin administration in therapeutic group. Fig. (5a, b) showed minimal edema and congestion with absence of necrosis, showing minimal lessened vacuolization in protective group.

The cardiomyopathy scores from all animals in each group are showed in Table 7. There was no significant difference between the severities of the lesion scores in the three groups. The most severe lesion score was found in Toxemic groups or in Therapeutic group. The least severe monocyte alterations were found in rats of the protective group.

The most important point in this work was mentioned in Table 8 which showed that serum taurine levels was markedly decreased in toxemic group, referring to that recorded in control group. Moreover, the therapeutic use of taurine did not significantly change the serum taurine level in rats. While the protective use of taurine showed a significant elevation in its serum level compared to that recorded in toxemic group.

Regarding to morphometric studies, the measurement of nuclear area in liver, kidney and heart cells in all groups were shown in Table 9.

Table 10 showed a significant increase in T3 and T4 in Toxemic group, Therapeutic groups and Protective groups referring to that observed in control group. Also there was a marked decrease in the level of cortisone in both therapeutic and protective groups.

DISCUSSION

In the present study, the possible use of the antioxidant taurine in ameliorating the adverse effects of toxemia during pregnancy was investigated. The female rat was used as an animal model for induction of hypertension by adriamycin injection. The injection with adriamycin led to a marked elevation in the tail systolic blood pressure (TSBP) due to the elevation of free radicals production, cardiotoxicity and nephrotoxicity of adriamycin. These elevations are due to angiotensin II and it can directly stimulate the epithelial sodium channels in the distal tubules and results in increased sodium reabsorption [2, 21, 37].

The kidney function, urea and creatinine measurements, showed marked improvements when taurine was administrated to ADR induced toxemia in rats. However, the improvement was better in the Protective group than in the Therapeutic group. These improvements were also confirmed by the nephropathy score into different ADR treated groups, which illustrated mild nephrotic lesions when taurine administrated protectively.

The histopathological architecture of the kidney in all adriamycin treated groups showed different degrees of necrosis and glomerular congestion; however, in protective group these abnormalities were markedly improved. Most of the described renal pathology of adriamycin was reported on light microscopy. However, renal pathology may be concluded indirectly by measuring the biochemical changes in renal functions rather than morphologic changes. The highly significant elevation in the levels of both blood urea and serum creatinine and the decrease in the morphometry of the renal cells in the same group were found.
Plate III. Histopathological changes in rat's heart tissue treated with Adriamycin and Taurine.

Fig. (1). Normal heart of the rat (control) showed absence of myofibrillar necrosis or vacuolization (H & E, x 225).

Fig. (2). Heart of rat after taurine administration showed the normal architecture of cardiac muscle. (H &E, x 225).

Fig. (3a). Heart of rat after ADR administration showed the extensive edema with vacuolization and severe necrosis (H & E, x 225).

Fig. (3b). Heart of rat after ADR administration showed the extensive edema with myofibrillar necrosis (H & E, x 225).
Table 7. Cardiomyopathy Score in Different Adriamycin Treated Rats

<table>
<thead>
<tr>
<th>Groups</th>
<th>Score 0</th>
<th>Score I</th>
<th>Score II</th>
<th>Score III</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number of No Changes</td>
<td>Number of Minimal Changes</td>
<td>Number of Moderate Changes</td>
<td>Number of Sever Changes</td>
</tr>
<tr>
<td>Toxemic group (n=10)</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>Therapeutic group (n=10)</td>
<td>0</td>
<td>3</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Protective group (n=10)</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>5</td>
</tr>
</tbody>
</table>

Plate IV. Histopathological changes in rat's kidney tissue treated with Adriamycin and Taurine.

Fig. (4a, b). Kidney of the rat in therapeutic group showed the necrosis of tubules and congestion of the glomeruli (H & E, x 225).

Fig. (5a, b). Kidney of rat in protective group showed a partial degeneration in the tubules and mild glomerular congestion. (H &E, x 225).
The latter observations may be attributed to a progressive generation of free radicals, which attack the kidney tissue and led to a disturbance in the lipid peroxidation levels. Therefore, the free radicals accelerate the cell damage and precipitate chronic glomerulonephritis [38-40]. While, the injection of rats with adriamycin leads to the elevation in the level of phospholipidosis enzymes in the lysosomes, these enzymes inhibit Na⁺-K⁺-ATPase which leads to increase in the free radical formation [41, 42].

The biochemical disturbances in the kidney functions were also suggested to be due to the ability of ADR to reduce phagocytic activity of the reticuloendothelial system [43]. Moreover, the nephrotoxicity of ADR to its ability to be accumulated in the renal cells through peritubular capillaries and pinocytotic reabsorption of drug from the glomerular filtrate, which were rapidly incorporated in lysosomes. Accordingly, lysosomal swelling followed by their rupture could have induced the degeneration of tubular cells [44, 45].

Plate V: Histopathological changes in rat’s liver tissue treated with Adriamycin and Taurine.

Fig. (4a, b). Liver of rat in therapeutic group showed the extensive diffuse fatty degeneration (H & E, x 225).
Fig. (5a). Liver of rat in protective group showed the mild congestion and absence of necrosis. (H & E, x 225).
Fig. (5b). Liver of rat in protective group showed a limited fatty change and vacuolization of the hepatocytes. (H & E, x 225).
Plate VI. Histopathological changes in rat's heart tissue treated with Adriamycin and Taurine.

Fig. (4a). Cardiac muscle of rat in therapeutic group the score "1" necrosis. (H & E, x 225).

Fig. (4b). Cardiac muscle of rat in therapeutic group the score "2" necrosis. (H & E, x 225).

Fig. (4c). Cardiac muscle of rat in therapeutic group the score "3" necrosis. (H & E, x 225).

Fig. (5a). Cardiac muscle of rat in protective group showed the minimal edema and congestion and absence of necrosis (H & E, x 225).

Fig. (5b). Cardiac muscle of rat in protective group showed the minimal and lessened vacuolization (H & E, x 225).
Regarding the hepatic impairment observed in this study and the role of taurine, showed that in Toxemic group, the liver enzymes (AST, ALT, ALP) and bilirubin were markedly elevated than control group. However, in Protective group, these elevations were significantly less than that recorded in Toxemic group and higher than Control group. On the other hand, lesser effect of taurine was observed when it was used therapeutically, where the latter enzymes showed a moderate decrease in their levels regarding toxemic group.

Seven rats treated with adriamycin during pregnancy showed marked nuclear degenerative changes with cytoplasmic vacuolization, dilatation in the sinusoidal spaces with congested blood vessels, in addition to hyperplasia in Kupffer cells. The latter pathological changes were grading as score III. These observations were also accompanied with marked decrease in the morphometry of there liver cells.

The hepato-pathological changes could be attributed to the toxicity of adriamycin on the mitochondrial membrane of liver cells, which exposed to the massive destructive effect of free radicals, which logically followed by inhibition in the synthesis of DNA and RNA in the liver tissues. The previous explanation was in harmony with the suggestion of [43, 46, 47].

It was found that hepatocellular damage was combined with elevation of all serum liver enzymes and there is a reduction in the serum protein and albumin by injecting the rats with adriamycin [48-50].

Lipid parameters showed attractive results observed in Protective group while the lipid parameter showed a marked decrease than that recorded in Toxemic group or in Therapeutic group. These values were higher than Control group in total cholesterol, triglycerides, HDL, and VLDL respectively.
Hyperlipidemia renal function in toxemic women or rats is usually followed with nephrotic syndrome [51,52] and causes deamination of protein in tissues [51, 53] or disturbance in the thyroid function [54] or alteration in the lipid peroxidation status [55, 56] and elevation of hydrogen peroxide and hydroxyl radicals’ impairment on lipid metabolism [57].

Moreover, hyperlipidemia in adriamycin induced nephrosis to the significant in carnitine level in heart which lead to increment in the formation of free fatty acids [26, 46, 58].

Hyperlipidemia per se, can induce coronary insufficiency and cardiomyopathy in toxemic pregnancy [4, 59]. Therefore, the marked hyperlipidemic pattern was observed in this work accompanied with severe cardiomyopathy score, and the decrease in morphometric nuclear area of cardiac cells recorded in toxemic pregnant rats support the observation of the same authors who considered heart failure as the main cause of death in severe Toxemic pregnancy. This terminal disease may occur directly through the toxicity or indirectly through loading the heart with massive water retention [60, 61] or through severe renal [5, 62] and hepatic impairment [46, 49, 63].

The adriamycin was considered as a strong cardiotoxic drug since more than twenty years ago [64, 65]. The authors recorded the high affinity of cardiolipin to adriamycin, which enter the cardiac cell via passive diffusion and induce extensive fragmentation in myofibrils, ribosomal constituents and mitochondria.

Same observations were also recorded [46, 47, 58] by pryingly, the main histopathological changes identified in the toxemic ADR treated rats were myofibrillar loss and cytoplasmic vacuolization, which were parallel to cardiomyopathy score 4 in stage II and in stage III recorded for them. These pathological changes were referred to many mechanisms such as sever cardiac ischemia [66] function in sarcoplasmic reticulum [26, 67], increase intracellular free radicals formation [39, 68] or loss of cardiac troponin from the lysised myofibrillar plasma membrane [26, 69].

The significant decrease in taurine concentration in serum of all toxemic pregnant rats is considered as crucial finding. It was proved that vascular resistance in pregnancy depends upon the balance between vasoconstrictors (angiotensin II, Throboxane-TXA2) and vasodilators (Prostacyline-PGI2). The latter vasodilator PGI2 synthesized by endothelium lining blood vessels and placental tissues, inhibits platelets aggregation and adherence, keeping blood vessels free of platelets and ultimately clots [70]. PGI2 was also considered as a potent vasodilator in the body [71]. Platelets on the other hand, synthesize (TXA2), a potent of platelet aggregation and vasoconstrictor, therefore, toxemia of pregnancy may represent defective in PGI2 production or a loss of response to it [72].

While taurine was considered as PGI2 stimulator [72] and a powerful antivasospastic drug [73,74]. Concomitantly, the levels of antioxidant activity (as taurine) correlate with plasma levels of PIG2 and TXA2 in pregnancy induced hypertension [63].

The nephroprotective effect of taurine was proved by many researches. Since, 1988 taurine was used to attenuate glomerulosclerosis and tubulo-interstitial fibrosis in rats with chronic puromycin aminoglycoside nephropathy [75, 76], nephropathy induced by lateral renal artery occlusion [77] or by CCl4 injection [78, 79] and by injection with monosodium glutamate [80] lowers the level of lipid peroxides in serum and kidney tissues. In addition, it was suggested that taurine has a nephroprotective effect against adriamycin-induced proteinuria and hyperlipidemia [57] and gentamycin-induced acute tubular necrosis [81] which was associated with nephritic syndrome [53]. The latter complication is one of the most precipitating factors of renal failure in toxemic pregnancy [2, 82]. Moreover, it was proved that taurine has protective effect against cyclosporine-A (hypertension and nephrotoxic substance) [20, 83] and it relaxes contracted aorta and inhibits the phenylephrine-induced contraction of renal and mesenteric arteries, therefore the action of taurine is related to potassium channel opening [23].

All these observations strongly support the marked enhancement in the kidney function and its microscopical architecture beside the improvement in the nephropathy score and morphometry observed in toxemic pregnant rats protectively treated with taurine in this work.

The hepatoprotective effect of taurine was investigated by many authors. It was postulated that taurine has cytoprotective effects on hepatocytes under hypoxic or hypoxic condition in the presence of Ca2+ [84, 85], protects liver against the hepatotoxic effect of CCl4 [16, 78, 79] and monosodium glutamate [16, 80, 86] that induced hepatocyte necrosis. Moreover, it was postulated that taurine can prevent the acute and chronic damage induced by oxidative agent by decreasing oxidative stress [87]. Furthermore, taurine protects the integrity of hepatic tissue by stabilizing the reactive oxygen species mediated lipid peroxidation and protein carbonyl formation [18] and prevents the cisplatin hepatotoxicity [19] in addition, hepatic steatosis could be ameliorated by administration of taurine [88, 89]. Moreover, it was suggested that taurine deficiency might be associated with development of cholestasis in liver of both animals and children [90].

There were marked improvements in the architecture of the hepatocytes, which were parallel to decreasing in all liver enzymes and bilirubin in the serum of toxemic pregnant rats protectively treated with taurine in this work. But the latter improvement was not obvious when taurine was used therapeutically. Supporting, the diminution in cytoplasmic vacuoles is the only difference observed in therapeutic group. However, in Protective group the main pathology is localized in score II (5) and I (2) with marked improvement in all degenerative changes (score III). Few hepatocytes showed architecture deeply stained nuclei and variable sized vacuoles. Most of the degenerated cells also suffered from either partial or complete loss of their boundaries.

The strongly suggestive hepatoprotective effect of taurine may be attributed to its inhibition effect on free radical formation or through scavenging the well formed radicals [91, 92]. It was postulated that taurine play a role in stabilizing the liver cell membrane through controlling Na⁺- K⁺- pump and Na⁺-K⁺- ATPase system therefore, it can
Possible Ameliorative Effect of Antioxidant (Taurine)

The Open Hypertension Journal, 2009, Volume 2 13

protect the hepatic cells from many toxic substances like adriamycin [93, 94].

Regarding heart, the cardioprotective role of taurine was the subject for many research projects in the last decade in normal and diabetic persons. It was proved that three processes that have been implicated in ischemic injury which are impaired calcium movement; altered osmoregulation and membrane remodeling. Because taurine affects all the three processes, it seemed logical that changes in the myocardial content of taurine might affect ischemic injury [13, 95, 96].

In 1999, It was demonstrated that taurine is able to increase calcium and the amplitude of calcium transient in both normal and diabetic cardiac myocytes [96]. In addition the effects of taurine appeared to be more pronounced in diabetic than control cells [97].

It was concluded that taurine depletion renders the heart resistance to injury caused by regional ischemia in isolated taurine-depleted rat’s hearts [95]. Also taurine deficiency was considered as main pathogenomic factor in precipitating cardiomyopathy in toxemic pregnant diabetic woman [98, 99]. Also, taurine was used as cardioprotective and renoprotective drug in spontaneously hypertensive rats [100]. Moreover, the cardioprotective potential of taurine was probably due to increase of the activity of free radical enzymes or to a counter action of free radicals by its antioxidant nature or to strengthening of myocardial membrane by its membrane stabilizing property [101].

Concomitantly, in 2008 serum taurine level was used in pregnant women as early marker of hypertension and to diagnose the completion –of toxemia during pregnancy [102].

In our study there was marked improvements in the histopathological architecture, cardiomyopathy score (3 in stage 0; 2 in stage 1, 2 in stage II and only 3 in stage III) and in morphometric nuclear area of the cardiac nuclei obtained in toxemic pregnant rat protectively treated with taurine.

The hypertension in experimental animal was not related to the pregnancy but was due to the toxemic effect of adriamycin. The elevation in systolic blood pressure in pregnant rats induced by adriamycin may be due to its hepatotoxicity, nephrotoxicity, hyperlipidemia, cardiotoxicity or due to its stimulating effect in T3, T4 and cortisone or all of them.

It has been suggested that there is a similarity in the mechanism(s) through which the toxemia of pregnancy in women or induced by adriamycin in pregnant rats, precipitate its pathological lesions. Therefore, adriamycin pregnant rats could be considered as a good model of complicated hypertensive pregnant women. Therefore, the significant protective effect of taurine against the different pathological lesions, observed in this work in toxemic rats, could stimulate our thinking of using it in toxemic women, specially because serum and placental taurine was found to be lower in pregnant induced hypertension toxemic women [102].

In conclusion, on the basis of these findings, we suggest that lowering in serum taurine concentration in toxemic pregnancy in rat model could be considered as one of the main pathological factors precipitating all the complications observed in toxemic pregnancy. Moreover, the successful use of taurine for management of nephropathies, hepatopathies and cardiomyopathies in toxemic rats, must attract our attention to think about to obtain evidence-based medicine data regarding taurine as early as possible (protectivel) in high risk or in suspected hypertensive pregnant women to guard against the serious maternal and neonatal complications occur in pregnancy induced hypertension.

REFERENCES


Possible Ameliorative Effect of Antioxidant (Taurine)

The Open Hypertension Journal, 2009, Volume 2  15


